Only a fifth of patients allowed AMD drugs

Eighty per cent of patients in England and Wales with wet age-related macular degeneration (AMD) will be denied treatment under draft guidance issued by NICE.

If implemented, the guidance would severely restrict the use of the anti-vascular endothelial growth factor drugs ranibizumab (Lucentis) and pegaptanib (Macugen).

Both drugs have already been approved by the Scottish Medicines Consortium.

But the NICE guidance says that only the 20 per cent of patients in whom both eyes have been affected by wet AMD should be given ranibizumab and that it should only be used in the better-seeing eye. The use of pegaptanib is not recommended.

Kevin Gregory-Evans, an ophthalmologist at the Western Eye Hospital in West London, said he was not surprised that NICE had restricted the use of the drugs but was very surprised by the severity of the restriction.

'Both drugs are effective and patients tend to do better with them than without them,' he said.

'It is totally unacceptable for NICE to restrict the use of ranibizumab to patients who have been affected in both eyes.

'The drug should be given early because it becomes harder to treat AMD when both eyes are affected.'

Recent studies have shown that you do not have to give patients the full course of drugs to improve their AMD, thus lowering the costs, he said.

'But NICE does not take this into account and bases its calculations on the cost of a full course of drugs,' he added.

The drugs are not funded in Northern Ireland.

- Live links at http://www.healthcarerepublic.com

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GPs hit out over 'unacceptable' bid to force them into 62,000-patient network

GPs hit out over 'unacceptable' bid to force them into 62,000-patient network

London GPs have hit out at plans to force them into a primary care network (PCN)...

Government facing legal action over state-backed GP indemnity

Government facing legal action over state-backed GP indemnity

A leading medical defence organisation is launching legal action against the government...

Guidelines for GPs based on 'opinion rather than evidence'

Guidelines for GPs based on 'opinion rather than evidence'

Many GP guidelines are based on 'opinion rather than evidence' and could drive up...

Wellbeing for GPs: Advice for newly-qualified GPs

Wellbeing for GPs: Advice for newly-qualified GPs

Dr Anish Kotecha offers new GPs some practical tips on how to ensure their wellbeing...

Hospital takeovers of GP practices 'against spirit of NHS long-term plan'

Hospital takeovers of GP practices 'against spirit of NHS long-term plan'

Vertical integration schemes that involve GP practices becoming subcontractors to...

NHS Counter Fraud Authority to investigate 'losses to fraud' in general practice

NHS Counter Fraud Authority to investigate 'losses to fraud' in general practice

The NHS Counter Fraud Authority has identified possible fraud around GP capitation...